GRCL News and Press, Gracell Biotechnologies Inc. From 05/16/22

Gracell Biotechnologies Inc. (GRCL) Q1 2022 Earnings Conference Call May 16, 2022 8:00 a.m. ET Company Participants Dr. William Cao - Founder, Chairman, and CEO Dr. Martina Sersch - CMO Dr. Kevin Xie - CFO Conference Call Participants Joe Catanzaro - Piper Sandler Kelly Shi - Jefferies Nick A...

Gracell Biotechnologies press release (NASDAQ:GRCL): Q1 GAAP EPS of -$0.07 in-line. As of March 31, 2022, the Company had RMB1,694.7 million (US$267.3 million) in cash and cash equivalents and short-term investments For further details see: Gracell Biotechnologies GAAP EPS of -$0.07 in-...

Presented early clinical data from a first-in-human Phase 1 investigator-initiated trial (IIT) of allogeneic TruUCAR candidate GC502 for relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) at AACR 2022; updated data to be presented at EHA 2022 Oral presentation...

Gracell Biotechnologies to Present Clinical Data on BCMA/CD19 Dual-targeting CAR-T GC012F in RRMM and B-NHL and CD19/CD7 Dual-directed Allogeneic CAR-T GC502 in B-ALL at EHA2022 Congress PR Newswire SAN DIEGO, Calif. , SUZHOU and SHANGHAI, China , May 12,...

SAN DIEGO and SUZHOU, China and SHANGHAI, China, May 04, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies...

SAN DIEGO, Calif., and SUZHOU, China, May 02, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cance...

Gracell Biotechnologies Announces Details of Oral Abstract Presentation at 2022 ASCO Annual Meeting PR Newswire Gracell to present longer-term follow-up clinical data evaluating GC012F, an autologous CAR-T therapeutic candidate dual-targeting BCMA and CD19, for the tre...

SAN DIEGO, Calif. and SUZHOU, China, April 22, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of canc...

Gracell Biotechnologies' Abstract on GC012F, a BCMA/CD19 Dual-targeting CAR-T Cell Therapy, Accepted for Presentation at 2022 ASCO Annual Meeting PR Newswire PALO ALTO, Calif. and SUZHOU, China , April 14, 2022 /PRNewswire/ -- Gracell Biotechnolo...

Gracell Biotechnologies to Present Data at AACR Annual Meeting 2022 Showcasing Early First-in-Human Results for GC502 in r/r B-ALL PR Newswire Allogeneic, off-the-shelf CAR-T therapy with CD19/CD7 dual-directed CAR shows promising early results in patients with r/r B-A...